Video

Dr. Mesa on Long-Term Data From the COMFORT Trials

Ruben A. Mesa, MD, Professor of Medicine, Division of Hematology & Medical Oncology, Mayo Clinic, discusses the long-term experience from the COMFORT-I and COMFORT-II trials in myelofibrosis.

Ruben A. Mesa, MD, Professor of Medicine, Division of Hematology & Medical Oncology, Mayo Clinic, discusses the long-term experience from the COMFORT-I and COMFORT-II trials in myelofibrosis.

Data from the COMFORT trials shows that most patients switched to ruxolitinib (from placebo or best alternative therapy). After the switch, patients saw benefits such as spleen size reduction and symptomatic improvement. These responses were durable as patients remained on ruxolitinib and experienced survival benefit.

Survival advantage was particularly noticeable in those who saw clear weight gain, reversible cachexia with the disease, and improvement in hypercholesterolemia.

Related Videos
Leah Backhus, MD, MPH, FACS, professor, University Medical Line, Cardiothoracic Surgery, co-director, Thoracic Surgery Clinical Research Program, associate program director, Thoracic Track, CT Surgery Residency Training Program, Thelma and Henry Doelger Professor of Cardiovascular Surgery, Stanford Medicine; chief, Thoracic Surgery, VA Palo Alto
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Medical Oncology, director, Center for Thoracic Cancers, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Chirag Shah, MD
Jason A. Mouabbi, MD
Roger Li, MD,
Brian I. Rini, MD, FASCO
Marc-Oliver Grimm, MD
David Samuel Dicapua Siegel, MD
Moritz Fürstenau, MD
Joseph Franses, MD, PhD